4-(3-溴苯基)吗啉 | 197846-82-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: 4-(3-溴苯基)吗啉
• 中文别名: 3-吗啉溴苯；1-溴-3-(4-吗啉-4-基)苯；4-(3-溴苯基)-吗啉
• 英文名称: 4-(3-bromophenyl)morpholine
• CAS: 197846-82-5
• 化学式: C₁₀H₁₂BrNO
• 分子量: 242.115
• InChiKey: RQMIVKDXRGZOBQ-UHFFFAOYSA-N

物化性质

• 沸点：
  341.1±37.0 °C(Predicted)
• 密度：
  1.433

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R22
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-(3-Bromophenyl)morpholine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-(3-Bromophenyl)morpholine
CAS number: 197846-82-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H12BrNO
Molecular weight: 242.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(3-溴苯基)吗啉 在 吡啶 、 copper(II) bis(trifluoromethanesulfonate) 作用下， 以 乙腈 为溶剂， 100.0 ℃ 、3.0 MPa 条件下， 反应 24.0h， 以45%的产率得到2-(N-(3-bromophenyl)formamido)ethyl formate
  参考文献：
  名称：

  胺中C（sp3）-C（sp3）键的实际催化裂解

  摘要：

  与它们普遍存在的形成相比，热力学稳定的C（sp 3）-C（sp 3）单键的选择性裂解是罕见的。本文中，我们描述了在空气存在下使用均相铜基催化剂进行此类转化的一般方法。这种新颖的方法的效用证明对C α -C β在> 70度胺具有优良的官能团耐受性键断裂。该转化建立了叔胺作为酰胺的一般合成子，并为其在例如天然产物和生物活性分子中的可扩展功能化提供了宝贵的可能性。

  DOI：

  10.1002/anie.201903019
• 作为产物：
  描述：

  4-溴-2-(n-吗啉基)苯甲醛 在 N,N-二甲基丙烯基脲 作用下， 反应 6.0h， 以88%的产率得到4-(3-溴苯基)吗啉
  参考文献：
  名称：

  邻氨基苯甲醛的无催化剂光脱羰

  摘要：

  几乎共识是，醛基（–CHO）的脱羰不仅需要通过过渡金属催化剂来介导，而且还需要严格的反应条件（高温和长反应时间）。在这项工作中，受“基于构象选择性的”设计策略的启发，我们打破了这一共识，并发现了醛基的无催化剂光脱羰基。它表明，脱羰基化可以用可见光照射能够容易地实现通过引入叔胺到邻醛基的-位置。在温和条件下，我们的光脱羰基化可以耐受各种各样的叔胺。此外，在精心设计的特殊底物上进行机理和实验的（QM）计算表明，我们的光脱羰基取决于醛基和叔胺的构象特异性，并通过异常的[1,4] -H位移和随后的[1,3] -H移位。

  DOI：

  10.1039/d0gc01256d

文献信息

• [EN] 2,3-DISUBSTITUTED 1 -ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS<br/>[FR] DÉRIVÉS 2,3-DISUBSTITUÉS DE 1-ACYL-4-AMINO-1,2,3,4-TÉTRAHYDROQUINOLÉINE ET LEUR UTILISATION COMME INHIBITEURS DE BROMODOMAINES
  申请人：GLAXOSMITHKLINE IP NO 2 LTD

  公开号：WO2014140076A1

  公开（公告）日：2014-09-18

  The present invention relates to novel compounds of formula (I), wherein R1 is C1-4alkyl; R2 is C1-4alkyl, C3-7cycloalkyl, -CH2CF3, -CH2OCH3 or heterocyclyl; R3 is C1-4alkyl, -CH2F, -CH2OH or -CH2O(O)CH3; R4 when present is as defined in claim 1; R5 when present is H, halo, hydroxy or C1-6alkoxy; A is -NH-, -O-, -S-, -SO-, -SO2-, -N(C1-4alkyl)- or -NC(O)(CH3)-; V is phenyl, heteroaromatic or pyridone any of which may be optionally substituted by 1, 2 or 3 substituents; W is CH or N; X is C or N; Y is C or N; and Z is CH or N; subject to the proviso that no more than 2 of W, X, Y and Z are N, pharmaceutical compositions containing such compounds and to their use as bromodomain inhibitors.

  本发明涉及式(I)的新化合物，其中R1为C1-4烷基；R2为C1-4烷基、C3-7环烷基、-CH2CF3、- 或杂环烷基；R3为C1-4烷基、-CH2F、- H或-CH2O(O)CH3；R4存在时如权利要求1所定义；R5存在时为H、卤素、羟基或C1-6烷氧基；A为-NH-、-O-、-S-、-SO-、-SO2-、-N(C1-4烷基)-或-NC(O)( )-；V为苯基、杂芳基或吡啶酮，其中任何一个可以选择性地被1、2或3个取代基取代；W为CH或N；X为C或N；Y为C或N；Z为CH或N；但W、X、Y和Z中不超过2个为N，含有这种化合物的药物组合物以及它们作为溴结构域抑制剂的用途。
• Palladium-Catalyzed Cross-Coupling Reaction of Tricyclopropylbismuth with Aryl Halides and Triflates
  作者：Alexandre Gagnon、Martin Duplessis、Pamela Alsabeh、Francis Barabé

  DOI：10.1021/jo702377h

  日期：2008.5.1

  The palladium-catalyzed cross-coupling reaction of tricyclopropylbismuth with aryl and heterocyclic halides and triflates is reported. The reaction tolerates numerous functional groups and does not require anhydrous conditions. The method was successfully extended to the cross-coupling of triethylbismuth.

  报道了钯催化的三环丙基铋与芳基和杂环卤化物以及三氟甲磺酸酯的交叉偶联反应。该反应可耐受许多官能团，并且不需要无水条件。该方法已成功地扩展到三乙基铋的交叉偶联。
• Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins
  申请人：Kroth Heiko

  公开号：US20110280808A1

  公开（公告）日：2011-11-17

  The present invention relates to novel compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. The present invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the preparation of medicaments for treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins. A method of treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins is also disclosed.

  本发明涉及一种新型化合物，可用于治疗与淀粉样蛋白相关的一组疾病和异常，如阿尔茨海默病，以及与淀粉样蛋白类似蛋白相关的疾病或病况。本发明的化合物还可用于治疗与视觉系统组织中的病理异常/变化相关的眼部疾病。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物制备用于治疗或预防与淀粉样和/或淀粉样类似蛋白相关的疾病或病况的药物的用途。还公开了一种治疗或预防与淀粉样和/或淀粉样类似蛋白相关的疾病或病况的方法。
• NEW PHENYLAZETIDINECARBOXYLATE OR -CARBOXAMIDE COMPOUNDS
  申请人：INVENTIVA

  公开号：US20170066717A1

  公开（公告）日：2017-03-09

  The invention relates to compounds of formula (I). where R, R 1 , R 2 , n, A and Cy have the meanings indicated in the description. The compounds of formula (I) are Nurr-1 modulators.

  这项发明涉及式(I)的化合物。 其中R、R1、R2、n、A和Cy的含义如描述中所示。 式(I)的化合物是Nurr-1调节剂。
• Visible‐Light‐Mediated Aerobic Oxidative C( <i>sp</i> ^<i>3</i> )−C( <i>sp</i> ^<i>3</i> ) Bond Cleavage of Morpholine Derivatives Using 4CzIPN as a Photocatalyst
  作者：Chun‐Lin Dong、Lan‐Qian Huang、Zhi Guan、Chu‐Sheng Huang、Yan‐Hong He

  DOI：10.1002/adsc.202100455

  日期：2021.8.3

  Herein, a metal-free strategy for the aerobic oxidative cleavage of the inert C(sp3)−C(sp3) bond was developed. Deconstruction of morpholine derivatives was conducted using visible light as an energy source and O2 as an oxidant under mild conditions. This procedure demonstrated suitable selectivity and functional group tolerance. Moreover, a possible mechanism involving a radical process was proposed

  在此，开发了一种用于惰性 C( sp 3 )-C( sp 3 ) 键有氧氧化裂解的无金属策略。以可见光为能源，O 2为氧化剂，在温和条件下进行吗啉衍生物的解构。该程序证明了合适的选择性和官能团耐受性。此外，基于一系列机制探索和控制实验，提出了涉及激进过程的可能机制。